Medicus Pharma Ltd (MDCX)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances
Medicus Pharma (NASDAQ:MDCX) is positioning its precision oncology-led pipeline for a series of clinical and regulatory milestones, with partnerships and licensing deals central to the next phase of development, the company said in a shareholder update marking its third anniversary. The Nasdaq-listed biotech said its priorities are to advance selected clinical and regulatory milestones, align organizational costs with those priorities, and pursue licensing and co-development opportunities.
Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA
Medicus Pharma (NASDAQ:MDCX) has submitted a seamless Phase 2b/3 registration-intent protocol to the US Food and Drug Administration for Teverelix, its long-acting GnRH antagonist for advanced prostate cancer patients at increased cardiovascular risk. The company said the stage-gated design starts with about 80 randomized patients, replacing a previously FDA-cleared, stand-alone 40-patient open-label dose-optimization study.
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment
Medicus Pharma (NASDAQ:MDCX) said a completed Phase 2 study of its SkinJect therapy showed all 90 enrolled patients finished treatment without discontinuations, data the company says will guide its next-stage registrational trial in a rare genetic skin cancer syndrome. The randomized, double-blind, multicenter trial enrolled patients across 10 US investigative sites, comparing two dose levels of SkinJect against a device-only microneedle comparator.
Medicus Pharma Ltd Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 52,643 | $23,490 | $4,885.27 | -$18,604.73 | -79.2% |
 May Hill Capital LLC May Hill Capital LLC | 50,622 | $87,391.15 | $4,733.16 | -$82,657.99 | -94.58% |
Medicus Pharma Ltd (MDCX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Medicus Pharma Ltd ever had a stock split?
Medicus Pharma Ltd Profile
| Biotechnology Industry | Healthcare Sector | Raza Bokhari CEO | NASDAQ (CM) Exchange | 58471K202 CUSIP |
| CA Country | 16 Employees | - Last Dividend | 9 Oct 2026 Last Split | - IPO Date |
Overview
Medicus Pharma Ltd stands out as a leading entity in the pharmaceutical industry, concentrated on the research, development, and bringing to market innovative health care solutions. The core mission of the firm is to cater to unmet medical needs through the creation of a diversified portfolio of therapeutic treatments, concentrating primarily on areas such as oncology, neurology, and immunology. With a heavy reliance on biotechnology and avant-garde medical research, Medicus Pharma Ltd is firmly positioned as a significant figure in the life sciences domain. The organization is deeply committed to enhancing the quality and efficacy of treatments, thereby contributing significantly to the elevation of global healthcare standards. Beyond its influence on the pharmaceutical landscape, Medicus Pharma Ltd is instrumental in enhancing the health and well-being of patients and healthcare systems worldwide. As a frontrunner in the market, it engages in collaborations with academic bodies and industry counterparts, aiming to stimulate innovation and hasten the delivery of potentially life-saving drugs.
Products and Services
The range of products and services offered by Medicus Pharma Ltd is extensive, with each category tailored to address specific healthcare challenges:
- Oncology Treatments: Medicus Pharma Ltd develops innovative therapies aimed at treating various forms of cancer. These treatments focus on improving patient outcomes and include targeted therapy, immunotherapy, and traditional chemotherapy. By leveraging the latest research in oncology, the company strives to offer more effective and less toxic options to patients.
- Neurology Solutions: In the realm of neurology, the company is dedicated to discovering treatments for neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Through cutting-edge research, Medicus Pharma Ltd aims to provide patients with treatments that can alleviate symptoms, halt disease progression, and improve quality of life.
- Immunology Therapies: Focusing on disorders of the immune system such as autoimmune diseases, Medicus Pharma Ltd is at the forefront of developing therapies that modulate the immune response. These treatments are designed to target underlying causes of immune-related conditions, offering new hope to patients suffering from diseases like rheumatoid arthritis, lupus, and inflammatory bowel disease.
Each product and service provided by Medicus Pharma Ltd encapsulates the company's commitment to pioneering healthcare advancements, ensuring that their offerings not only meet the highest standards of safety and effectiveness but also address the evolving needs of patients and healthcare professionals around the globe.
Contact Information
